Autoinjectors Market to Reach USD 299 Billion by 2035 at 5.7% CAGR | SHL Medical, Ypsomed, Owen Mumford

The global autoinjectors market, valued at USD 170 billion in 2025, will reach USD 181 billion in 2026 and climb to USD 299 billion by 2035, advancing at a CAGR of 5.7% over the forecast period. The growth reflects accelerating demand for self-administration devices across chronic disease management, a wave of biosimilar launches entering autoinjector formats, and a measurable shift in patient care from clinical settings to home environments.

To access the full findings, request a free sample of the report at https://www.rootsanalysis.com/reports/autoinjectors-market/request-sample.html

Market Overview
Autoinjectors are spring-loaded, pre-filled devices that deliver a fixed drug dose at the press of a button, eliminating the need to draw medication from a separate vial. Their appeal is straightforward: they reduce injection errors, improve patient adherence, and make self-medication viable for conditions that once demanded clinical supervision. EpiPen set the category standard for emergency use, while blockbuster biologics such as Humira Pen and Rebif Rebidose have demonstrated the commercial case for autoinjector-formatted drugs at scale.

The biosimilar pipeline is now extending that commercial logic further. Sandoz launched Pyzchiva, a ustekinumab biosimilar, in an autoinjector format in Europe in May 2025. Celltrion received a positive CHMP opinion for the autoinjector formulation of Omlyclo, an omalizumab biosimilar, in March 2025. As leading biologics progressively lose patent protection, biosimilar developers are treating autoinjector integration as a strategic vehicle for product differentiation and patient retention.

Investment activity signals confidence in the sector's trajectory. In February 2026, Eco-Inject secured £5.2 million in equity funding to scale next-generation, low-carbon autoinjectors, expand production capacity, and meet regulatory requirements for global markets. In November 2025, SHL Medical announced it had shipped 1.5 billion autoinjectors across its product portfolio, a milestone that reflects both manufacturing scale and the category's breadth of adoption.

Key Growth Drivers
Rising chronic disease burden. Nearly 95% of adults globally suffer from at least one chronic illness, according to NCOA research. Conditions including diabetes, rheumatoid arthritis, multiple sclerosis, and asthma generate sustained, long-term demand for injectable therapies, and autoinjectors are increasingly the preferred delivery format for patients managing these conditions at home.

Shift toward home-based care. The home care end-user segment captures approximately 85% of the overall autoinjectors market share in 2026. Patients with chronic conditions are moving away from facility-based injections due to cost, privacy concerns, and the inconvenience of clinical visits. Autoinjectors make this transition clinically safe and practically achievable.

Biosimilar and biologic pipeline expansion. Patent expiries on major biologics are creating openings for biosimilar developers to combine new molecules with autoinjector platforms. Boehringer Ingelheim's Cyltezo and Coherus Biosciences' Udenyca are two approved biosimilars already available in autoinjector formats, and the pipeline indicates this trend will intensify through 2035.

GLP-1 and weight management drugs. Autoinjectors delivering drugs for weight loss are projected to grow at a higher CAGR than any other target indication over the forecast period. Rising obesity rates and patients' preference for discreet, convenient self-administration are the primary factors behind this acceleration.

Connected device integration. Manufacturers are embedding Bluetooth connectivity, smart dosing, and adherence-tracking features into next-generation devices. Owen Mumford's UniSafe reusable autoinjector and Gerresheimer's partnership with Portal Instruments for the PRIME Nexus connected platform, announced in September 2025, illustrate where product development is heading.

Market Segmentation
The autoinjectors market segments across usability, route of administration, molecule type, actuation mechanism, container volume, end user, and target indication. By usability, disposable autoinjectors dominate with approximately 95% of the overall market in 2026, driven by their ready-to-use design and elimination of sterilization requirements. Reusable autoinjectors, however, are the fastest-growing usability segment, advancing at a CAGR of more than 7% through 2035.

By type of molecule delivered, protein-based drugs hold the largest share at around 45% in 2026, with insulin as the most widely administered protein via autoinjector. Peptide-delivering autoinjectors are the fastest-growing molecular sub-segment, with a projected CAGR exceeding 12%. By container volume, the 1-2 mL range holds approximately 55% share, while devices capable of storing more than 2 mL are the fastest-growing volume segment at a CAGR of 7.6%. By target indication, rheumatoid arthritis accounts for close to 40% of the current market.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/autoinjectors-market/request-quote.html

Regional Insights
North America accounts for approximately 55% of the global autoinjectors market in 2026 and will maintain that dominance through 2035. More than 40% of autoinjector manufacturers globally are based in North America, providing a structural advantage in supply chain depth, regulatory familiarity, and proximity to major biopharmaceutical clients. The region's high rates of chronic disease diagnosis and well-established reimbursement infrastructure further reinforce that position.

Asia-Pacific is the fastest-growing regional market, with a projected CAGR exceeding 8.0% through 2035. Rising incidence of diabetes and rheumatoid arthritis, improving diagnosis rates, and broader healthcare access programs are the primary demand drivers. Europe holds the second-largest share globally, with 39% of autoinjector manufacturers operating in the region and an active regulatory environment that continues to accelerate biosimilar approvals.

Competitive Landscape
The autoinjectors market features more than 50 manufacturers and over 145 commercial or development-stage devices. Key companies profiled in the Roots Analysis report include SHL Medical, Owen Mumford, Ypsomed, Elcam Medical, Union Medico, Aptar Pharma, Gerresheimer, Novo Nordisk, Eli Lilly and Company, Amgen, Sanofi, Teva Pharmaceuticals, Novartis, Merck, Recipharm, Kindeva, PreciHealth, and Jiangsu Delfu Medical Device, among more than 120 additional firms. Approximately 80% of commercially available autoinjectors feature a fully automatic needle actuation mechanism, reflecting industry consensus around patient ease of use. Competitive activity is concentrated on three fronts: connected device capabilities, high-volume and large-molecule delivery formats, and geographic manufacturing expansion to serve Asia-Pacific demand. Partnership activity is accelerating; in January 2025, Aktiv Medical signed a co-development agreement with a global pharmaceutical company to develop a high-concentration, large-dose autoinjector using its PenPal platform.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/autoinjectors-market/293.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.